Nexavar® India
On 9 March 2012, a decision taken by India’s Controller General of Patents, Designs and Trademarks revived a drawn-out debate on the use and abuse of intellectual property rights in international commerce. The ruling granted a non-exclusive and non-assignable compulsory license to Natco Pharma to manufacture and sell a generic version of Bayer’s Nexavar – a drug used to treat advanced-stage liver and kidney cancer. Hyderabad-based Natco would sell a monthly dose of the life-saving medicine for INR 8,800 ($172), i.e. at a discount of 97% on the innovator price, and would pay 6% royalties to Bayer. Although the decision was applauded by NGOs and patient advocacy groups, others hoped that the case would trigger a much needed review of relevant competition and trade policy standards, of the legitimacy of corporate versus national industrial policy objectives, as well as of the respective roles of emerged versus emerging markets and those of states versus businesses in funding research and providing healthcare. The case provides a starting point for that discussion.
Bayer
2012
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Navigate Trump's policy shifts with a clear framework to assess business risks, plan contingencies, and stay ahead in uncertain times. Prepare for what’s next.
Given the world’s many challenges, the ability to forge effective alliances across business, government, the non-profit sector, and academia has become essential to building durable solutions. Here are eight steps to guide you through the process.
Without a robust geopolitical radar, successfully navigating geopolitics is more luck than judgment.
Here are three strategic lessons from the tramp shipping industry.
Here are three strategic lessons from the tramp shipping industry.
Why the market for new year predictions is broken and how executives can better use forecasts to discern the implications for their companies.
Strategic thinking is key to success. Overcome common excuses and develop the skills to navigate change, drive innovation, and prepare for future business challenges.
Officially, brands executives continue to display confidence that big luxury will shrug off the 2024 downturn as a cyclical one. They see it as the product of the combined collapse of real estate prices in China and a return to normalcy after the ...
Did our predictions for 2024 come true, a turbulent election year, bitcoin and CBDC, COP29 and electric cars, China, EU integration and Euro football
Did our predictions for 2024 come true, a turbulent election year, bitcoin and CBDC, COP29 and electric cars, China, EU integration and Euro football
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications